World Health Organization (WHO) statement
The World Health Organization (WHO) underscores that the hepatitis B birth dose vaccine is an effective, and essential public health intervention, with a proven record. It prevents life‑threatening liver disease by stopping mother‑to‑child transmission at birth. It has been used for over three decades, with more than 115 countries including it in their national schedules. Protecting newborns with a timely birth dose not only provides individual benefit but is also central to national and global elimination efforts.
In response to recent questions from the media, WHO would like to state the following:
WHO is aware of the proposed randomized controlled trial on the hepatitis B birth dose vaccine in Guinea‑Bissau. Based on questions raised in publicly available information and consultation with relevant experts, WHO has significant concerns regarding the study’s scientific justification, ethical safeguards, and overall alignment with established principles for research involving human participants.
Read the full statement here.
Source : World Health Organization
Related HIV and Co-Infections News
-
[Open letter] Civil society demands access strategy for Merck’s promising long-acting HIV prevention pill covering all LMICs
-
aidsmap: Immigration and poverty tied to heightened HIV risk in the Netherlands
-
Infectious Disease Advisor: Mobile telemedicine improves hepatitis C treatment uptake in rural areas
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.